PT-141 dosage

Protocol

1. 1

   Reconstitute the vial

   Vyleesi ships as a pre-filled 1.75 mg autoinjector and requires no reconstitution. Compounded vials are typically 10 mg lyophilized powder; reconstituted with 1 mL bacteriostatic water this gives 10 mg/mL, and a 1 mg dose draws 10 units on a U100 insulin syringe.

   Open tool →
2. 2

   Measure the dose

   Typical PT-141 dose is 1.75 mg (Vyleesi label: 1.75 mg subcutaneous as needed, no more than once per 24 hours and no more than 8 doses per month. Off-label male ED use: 1 to 2 mg.). Use a weight-based calculator for individual adjustments.

   Open tool →
3. 3

   Set the frequency

   Administer as needed (max once per 24 hours, max 8 per month). Half-life of 2.7 hours anchors the dosing interval.

   Open tool →
4. 4

   Cycle if needed

   On-demand only. Not used continuously due to sustained-blood-pressure concerns.

   Open tool →
5. 5

   Monitor for side effects

   Watch for: nausea (~40%); flushing; headache; injection-site reactions. Stop or reduce dose if tolerability breaks down.

Why this dose

Synthetic agonist of melanocortin receptors with preference for MC4R, expressed in hypothalamic and limbic circuits regulating sexual motivation. Engages central pathways distinct from peripheral PDE5-mediated vasodilation.

The typical dose (1.75 mg) reflects Vyleesi label: 1.75 mg subcutaneous as needed, no more than once per 24 hours and no more than 8 doses per month. Off-label male ED use: 1 to 2 mg.. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

PT-141 is administered via the subcutaneous route. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose.

Onset of action runs around 45 minutes after administration. Peak effect lands near 1.5 hours post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Plasma half-life ~2.7 hours. Sexual-desire window is typically ~6 hours after a single dose.

Cycling and tolerance

On-demand only. Not used continuously due to sustained-blood-pressure concerns.

The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.

Effects to expect at typical dose

• Cyclic 7-amino-acid synthetic peptide and melanocortin receptor agonist (MC4R-preferring)
• FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder in pre-menopausal women
• Acts centrally on hypothalamic sexual-desire circuits rather than peripherally on vasculature
• On-demand dosing: subcutaneous 1.75 mg approximately 45 minutes before sexual activity
• Common adverse effects: nausea (~40%), flushing, headache, injection-site reactions, hyperpigmentation
• Off-label male ED use is documented but not FDA approved; mechanism is distinct from PDE5 inhibitors

Side effects and interactions

Common side effects

• nausea (~40%)
• flushing
• headache
• injection-site reactions
• hyperpigmentation (focal, gums, face, breasts)

Notable interactions

• naltrexone (oral) (major): bremelanotide reduces oral naltrexone exposure significantly; avoid co-administration
• antihypertensives (moderate): transient BP rise after bremelanotide can offset BP control
• PDE5 inhibitors (sildenafil, tadalafil) (minor): no documented adverse interaction; mechanisms are non-overlapping

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full PT-141 profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

allowed

DEA / Rx

Rx only (not a controlled substance) for the FDA-approved Vyleesi formulation

Pregnancy

Not recommended; contraindicated during pregnancy per Vyleesi label

Legal status

Prescription only as Vyleesi; FDA-approved 2019 for HSDD in pre-menopausal women. Compounded versions sold off-label for male sexual function are research-use-only grey market.

Do not use if

• uncontrolled hypertension
• established cardiovascular disease
• pregnancy
• naltrexone co-administration (reduces opioid efficacy due to MC receptor crosstalk)

Related research